2023-05-09 06:55:18 ET
- Eagle Pharmaceuticals press release ( NASDAQ: EGRX ): Q1 Non-GAAP EPS of $1.26 beats by $0.27 .
- Revenue of $66.3M (-42.8% Y/Y) beats by $2.97M .
- Q1 2023 net sales of PEMFEXY totaled $22.9 million; Eagle estimates that it has an approximate 15% share in commercial (non-340B) pemetrexed market for the second quarter of 2023 to date
- Company reaffirms full year guidance; adjusted EBITDA of $74.0 - $80.0 million and adjusted non-GAAP earnings per share of $4.20 - $4.53 vs $4.24 consensus
For further details see:
Eagle Pharmaceuticals Non-GAAP EPS of $1.26 beats by $0.27, revenue of $66.3M beats by $2.97M